To manage these toxicities, clinicians employ a range of strategies. The administration of tocilizumab, an anti-IL-6 receptor antibody, is commonly used to mitigate the effects of CRS. For neurotoxicity, corticosteroids and other supportive measures may be administered. Close monitoring in a hospital setting is essential during the initial phase of treatment to swiftly address any adverse reactions.
